Jonathan Kaufman

LaunchCyte LLC (LaunchCyte) is a venture capital firm founded in 2000 by Tom A.Petzinger and Barbara Bailey Carryer. The firm is headquartered in Pittsburgh, Pennsylvania.

Crystalplex Corp. operates a biochemistry and diagnostics laboratory that specializes in nanotechnology for the life sciences industry. Its proprietary technology, SapphireTM QDs provides a stable crystal design, flexible polymer matrix morphology, and meets environmentally responsible yet demanding performance requirements for high-end consumer electronics applications such as liquid crystal display televisions, displays, and high-CRI architectural lighting. The company was founded by Thomas A. Petzinge Jr. in 2004 and is headquartered in Pittsburgh, PA.

Reaction Biology Corp. specializes in kinase and epigenetic HTS and profiling services. It offers radiolabeled biochemical assays available for multiple enzyme classes including: Kinase Assays, HMT Assays, and HDAC Assays. Its products include Methyltransferase, IDH proteins, Apoptosis, DNA Demethylation, Apoptosis and NQOs. The company was founded by Scott L. Diamond in 2001 and is headquartered in Malvern, PA.

Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.

Proteopure, Inc. develops and markets sample protein preparation kits. The company was founded on May 3, 2006 and is headquartered in Pittsburgh, PA.

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.